Circulating immune checkpoints predict heart failure outcomes

Circulating immune checkpoints predict heart failure outcomes

Abstract Aims There are limited data examining the role of immune checkpoint (IC) ligands in the pathophysiology of heart failure (HF). Therefore, we explore this in three HF animal models and in three different human cohorts (healthy, stable, and worsening HF). Methods and results Transcriptomic an...

Descripció completa

Dades bibliogràfiques
Autors principals:	Elles M. Screever, Laura I.E. Yousif, Javid J. Moslehi, Joe‐Elie Salem, Adriaan A. Voors, Herman H.W. Silljé, Rudolf A. deBoer, Wouter C. Meijers
Format:	Article
Idioma:	English
Publicat:	Wiley 2023-08-01
Col·lecció:	ESC Heart Failure
Matèries:	Immune checkpoints PD‐L1 PD‐L2 Galectin‐9 Heart failure
Accés en línia:	https://doi.org/10.1002/ehf2.14304

Ítems similars

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
per: Douglas B. Johnson, et al.
Publicat: (2019-05-01)

Checkpoint Inhibition in Myeloma: Opportunities and Challenges
per: Federica Costa, et al.
Publicat: (2018-09-01)

The role of immune checkpoints in cardiovascular disease
per: Laura I. Yousif, et al.
Publicat: (2022-10-01)

Enhancing cancer care with improved checkpoint inhibitors
per: Vickram A S, et al.
Publicat: (2024-10-01)

Checkmate with checkpoint inhibitors: New paradigm in immunotherapy
per: Ruby Dhar, et al.
Publicat: (2023-04-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
per: Kazuhiko Hashimoto, et al.
Publicat: (2020-07-01)

Immune Checkpoint in Glioblastoma: Promising and Challenging
per: Jing Huang, et al.
Publicat: (2017-05-01)

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
per: Juwon Lee, et al.
Publicat: (2021-07-01)

Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
per: Ruiting Li, et al.
Publicat: (2021-06-01)

On Demand Biosensors for Early Diagnosis of Cancer and Immune Checkpoints Blockade Therapy Monitoring from Liquid Biopsy
per: Sai Mummareddy, et al.
Publicat: (2021-12-01)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
per: Tianrui Yang, et al.
Publicat: (2021-02-01)

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
per: Jan Willem Kleinovink, et al.
Publicat: (2017-04-01)

Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression
per: Sebastian Marwitz, et al.
Publicat: (2017-05-01)

Immune Checkpoint Inhibitors in Cancer Therapy
per: Yavar Shiravand, et al.
Publicat: (2022-04-01)

Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors
per: YU Lin, et al.
Publicat: (2021-08-01)

The Role of Immune Checkpoint Inhibitors in Cancer Therapy
per: Ahmed M. Basudan
Publicat: (2022-12-01)

The role of immune checkpoint inhibitors in prostate cancer
per: Gabriel Surdacki, et al.
Publicat: (2019-03-01)

Editorial: The Roles of Checkpoint Inhibitors in Inflammatory Diseases
per: Andreas von Knethen, et al.
Publicat: (2021-10-01)

Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
per: Alberto Bongiovanni, et al.
Publicat: (2021-05-01)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
per: Ya Xu, et al.
Publicat: (2020-10-01)

Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis
per: Edyta Zyla, et al.
Publicat: (2021-08-01)

The Neonatal Innate Immune Response to Sepsis: Checkpoint Proteins as Novel Mediators of This Response and as Possible Therapeutic/Diagnostic Levers
per: Emily Hensler, et al.
Publicat: (2022-07-01)

Key questions about the checkpoint blockade-are microRNAs an answer?
per: Mihnea Dragomir, et al.
Publicat: (2018-06-01)

Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
per: Maria Georganaki, et al.
Publicat: (2018-12-01)

Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA
per: William L. Redmond, et al.
Publicat: (2023-02-01)

The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors
per: Reid P. Bissonnette, et al.
Publicat: (2021-08-01)

Advances in immune checkpoint inhibitors for hepatocellular carcinoma
per: Ji Won Han, et al.
Publicat: (2021-09-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
per: Kübra KAHVECİ, et al.
Publicat: (2019-12-01)

Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation
per: Zachary S. Buchwald, et al.
Publicat: (2018-12-01)

Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis
per: Amjad Zafar, et al.
Publicat: (2024-11-01)

The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors
per: Jiaxin Zhou, et al.
Publicat: (2022-07-01)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
per: Adel Naimi, et al.
Publicat: (2022-04-01)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
per: Zhanjun Guo, et al.
Publicat: (2022-03-01)

Profiling targetable immune checkpoints in osteosarcoma
per: Troy A McEachron, et al.
Publicat: (2018-12-01)

The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges
per: Deniz Can Guven, et al.
Publicat: (2022-10-01)

Commentary: Chronic PD-1 Checkpoint Blockade Does Not Affect Cognition or Promote Tau Clearance in a Tauopathy Mouse Model
per: Kuti Baruch, et al.
Publicat: (2020-05-01)

NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy
per: Leona Raskova Kafkova, et al.
Publicat: (2024-02-01)

Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer
per: Shuai Wang, et al.
Publicat: (2018-08-01)

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
per: Silvia Pesce, et al.
Publicat: (2019-06-01)

In Search of Better Peptide-(Derived from PD-L2)-Based Immune Checkpoint Inhibitors
per: Boris Klebansky, et al.
Publicat: (2024-05-01)